ライフサイエンスコーパス: prothrombin complex

1 pathway when FXa is well-saturated with the prothrombin complex.

2 es of the membrane-bound factor Xa-factor-Va-prothrombin complex.

3 Four-factor prothrombin complex concentrate (4-PCC) is recommended f

4 orts suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood produc

5 nical trial to compare nonactivated 4-factor prothrombin complex concentrate (4F-PCC) with plasma for

6 pared the efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) with that of pl

7 measures and biomarkers by using a 4-factor prothrombin complex concentrate (4F-PCC).

8 Data on the use of activated prothrombin complex concentrate (aPCC) for the managemen

9 n rates and blood loss in patients receiving prothrombin complex concentrate (PCC) compared with plas

10 efficacy of fresh frozen plasma (FFP) versus prothrombin complex concentrate (PCC) in patients with V

11 Preliminary trials indicate that 4-factor prothrombin complex concentrate (PCC) may be a suitable

12 actice include fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC).

13 tal of 1832 patients (967 receiving 4-factor prothrombin complex concentrate [4F-PCC]; 525, andexanet

14 therapies that promote formation of fibrin (prothrombin complex concentrate [PCC], activated PCC [aP

15 BEST PRACTICE ADVICE 7: The 4-factor prothrombin complex concentrate contains both pro- and a

16 ecombinant activated factor VII or activated prothrombin complex concentrate did not alter the delaye

17 rventional treatment was needed in 37.8% and prothrombin complex concentrate in 9.1%.

18 circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent rever

19 rgent reversal with frozen plasma versus the prothrombin complex concentrate Octaplex.

20 Prothrombin complex concentrate or FP (3 U for patients

21 clinical effectiveness of andexanet alfa or prothrombin complex concentrate to reverse factor Xa inh

22 ntial hematoma expansion (43% [12 of 28] for prothrombin complex concentrate vs 29% [5 of 17] for no

23 The (weighted) mean effectiveness for prothrombin complex concentrate was 88% at 12 hours and

24 hrombotic event rates for andexanet alfa and prothrombin complex concentrate were 10.7% and 3.1%, res

25 ng administration of hemostatic factors (eg, prothrombin complex concentrate), were left to the discr

26 ntial ability of a low dose of the activated prothrombin complex concentrate, FEIBA, to reestablish h

27 complex concentrate vs 29% [5 of 17] for no prothrombin complex concentrate, P = .53), or on the occ

28 agents with a fast onset of action, such as prothrombin complex concentrate, recombinant factor VIIa

29 pplied to guide the dosing of fibrinogen and prothrombin complex concentrate, which are selectively u

30 all, 57% (35 of 61) of the patients received prothrombin complex concentrate, with no statistically s

31 rfarin anticoagulation with frozen plasma or prothrombin complex concentrate.

32 ity was 23.3% for andexanet versus 15.8% for prothrombin complex concentrate.

33 atients receiving usual care, 85.5% received prothrombin complex concentrate.

34 es were 5.0% for andexanet alfa and 1.9% for prothrombin complex concentrate.

35 dies were included (andexanet: 438 patients; prothrombin complex concentrate: 1,278 patients).

36 ated bleeding who were treated with 4-factor prothrombin complex concentrates (n = 2,688), idarucizum

37 Prothrombin complex concentrates (PCC) are fractionated

38 romboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the manageme

39 Four-factor prothrombin complex concentrates (PCCs) have logistical

40 Multiple guidelines suggest using prothrombin complex concentrates (PCCs) in these patient

41 Nonspecific hemostatic agents such as prothrombin complex concentrates and recombinant factor

42 xpanded available therapeutic options beyond prothrombin complex concentrates and their activated for

43 Recombinant factor VIIa and activated prothrombin complex concentrates are similarly effective

44 tients with FII or FV deficiencies, for whom prothrombin complex concentrates or fresh frozen plasma

45 of coagulation factors (fresh frozen plasma, prothrombin complex concentrates or recombinant activate

46 ts should receive a DOAC reversal agent (eg, prothrombin complex concentrates, idarucizumab, or andex

47 outcomes associated with the use of 4-factor prothrombin complex concentrates, idarucizumab, or andex

48 r hemostasis with antifibrinolytic agents or prothrombin complex concentrates, which are widely avail

49 he coagulation factor levels and contents of prothrombin complex concentrates; ambiguity about the op

50 therapy; the variability in availability of prothrombin complex concentrates; the variability in the

51 eal a function for autocatalysis of the vWbp.prothrombin complexes during initiation of blood coagula

52 othrombin triggers formation of an active SC.prothrombin* complex that cleaves host fibrinogen to Fbn